Soujanya Ravi, Author at PharmaDeviceNews

How Pacira BioSciences is aligning EXPAREL with value-based orthopedic care trends

Find out how Pacira BioSciences is positioning EXPAREL within value-based orthopedic care and opioid-sparing recovery trends.

How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.

BridgeBio Pharma, Inc.’s BBP-418 wins FDA Priority Review for LGMD2I/R9. Discover what this could mean for rare muscular dystrophy treatment.

Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.

RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.

Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.

Can Eli Lilly and Company’s VERVE-102 transform cholesterol treatment through one-time gene editing? Explore the risks, data, and implications.

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.

Assembly Biosciences is expanding ABI-6250 beyond HDV into PBC and PSC. Find out why NTCP inhibition is gaining industry attention.